Atrial fibrillation associated with tiotropium in patients with pre-existing arrhythmia: a case report

doi:10.5246/jcps.2015.03.024

Journal of Chinese Pharmaceutical Sciences ›› 2015, Vol. 24 ›› Issue (3): 192-194.DOI: 10.5246/jcps.2015.03.024

• Case report • Previous Articles Next Articles

Atrial fibrillation associated with tiotropium in patients with pre-existing arrhythmia: a case report

Yanhong Wei^1,2, Liping Yang^1*, Yatong Zhang¹, Hong Shao³

1. Department of Clinical Pharmacy, Beijing Hospital, Beijing 100730, China
2. Department of Pharmacy, Peking University Shougang Hospital, Beijing 100144, China
3. Department of Pharmacy, Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2014-04-17 Revised:2014-11-28 Online:2015-03-29 Published:2014-11-28
Contact: Tel.: 86-10-85133637

Abstract

Abstract:

Inhaled anticholinergic agent tiotropium is widely used in the treatment of chronic obstructive pulmonary disease (COPD). However, it has pro-arrhythmic and pro-ischaemic effects, which can potentially increase the risk of serious cardiovascularevents, especially in patients with pre-existing arrhythmias. We presented a 79-year-old man with a medical history of arrhythmia, who developed atrial fibrillation after used tiotropium 18 μg daily for two weeks. We urge the caution of pro-arrhythmic effect of tiotropium. Healthcare professionals should be aware of the potential effect when prescribing tiotropium to patients with known cardiac rhythm disorders.

Key words: Tiotropium, Atrial fibrillation, Adverse effects, Patient education

CLC Number:

R711

Supporting:

Yanhong Wei, Liping Yang, Yatong Zhang, Hong Shao. Atrial fibrillation associated with tiotropium in patients with pre-existing arrhythmia: a case report[J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(3): 192-194.

References

[1] The Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. This article can be found online at http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf (accessed 2014 Apr 15).

[2] Electronic Medicines Compendium. Spiriva Handihaler—Summary of Product Characteristics. 2013. This article can be found online at http://www.medicines.org.uk/emc/medicine/10039/SPC/Spiriva+18+microgram+inhalation+ powder%2c+hard+capsule/ (accessed 2014 Apr 15).

[3] Singh, S.; Loke, Y.K.; Enright, P.; Furberg, C.D. Thorax. 2013, 68, 114-116.

[4] Jara, M.; Lanes, S.F.; Wentworth III, C.; May, C.; Kesten, S. Drug Saf. 2007, 30, 1151-1160.

[5] Anh, D.; Marine, J.E. Heart Fail Rev. 2004, 9, 139-147.

[6] Gregory, M.D.; Mersfelder, T.L.; Jamieson, T. Ann. Pharmacother. 2010, 44, 391-393.

[7] Naranjo, C.A.; Busto, U.; Sellers, E.M.; Sandor, P.; Ruiz, I.; Roberts, E.A.; Janecek, E.; Domecq, C.; Greenblatt, D.J. Clin. Pharmacol. Ther. 1981, 30, 239-245.

[8] MHRA. Drug Safety Update. 2010,4,H2. This article can be found online at http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con099854.pdf (accessed 2013 Sep 30).

[9] Electronic Medicines Compendium. Spiriva Respimat—Patient Information Leaflet 2013. This article can be found online at http://www.medicines.org.uk/emc/medicine/ 20547/PIL/Spiriva+Respimat+2.5+microgram%2c+solution+ for+inhalation/ (accessed 2014 Apr 15).

[10] Electronic Medicines Compendium. Spiriva Respimat—Summary of Product Characteristics 2013. This article can be found online at http://www.medicines.org.uk/emc/medicine/20134/SPC/Spiriva+Respimat+2.5+micrograms+ solution+for+inhalation/ (accessed 2014 Apr 15).

[11] Gault, M.H.; Longerich, L.L.; Harnett, J.D.; Wesolowski, C. Nephron. 1992, 62, 249-256.

Atrial fibrillation associated with tiotropium in patients with pre-existing arrhythmia: a case report

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

Comments

[1]	Weina Yu, Youyi Xiong, Zhuo Chen, Fang Wang. Alpha-1-acid glycoprotein as potential predictive biomarker of docetaxel adverse effects in breast cancer patients [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(12): 895-899.
[2]	Xiaoke Guo, Zheng Shen, Peng Yu, Hongxi Chu, Yiqun Tang, Qidong You* . Discovery of benzamide derivatives as potent Kv1.5 inhibitors [J]. , 2012, 21(6): 553-560.